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Abstract 
Objective: To describe the detailed associations of albuminuria among a 
contemporary cohort of Aboriginal and Torres Strait Islander people to inform 
strategies for chronic kidney disease prevention and management. 
Methods: A cross-sectional analysis of Indigenous participants of the eGFR Study.   
Measures: Clinical, biochemical and anthropometric measures were collected 
(including body-circumferences, blood pressure (BP); triglycerides, HbA1c, liver 
function tests, creatinine; urine- microscopic-haem, albumin: creatinine ratio (ACR), 
prescriptions- angiotensin converting enzyme inhibitor or angiotensin receptor II 
antagonist (ACEI/ARB).  Albuminuria and diabetes were defined by an ACR>3.0 
mg/mmol, and HbA1c≥48 mmol/mol or prior history respectively.  Waist: hip ratio 
(WHR), and estimated glomerular filtration rate (eGFR) were calculated. ACR was 
non-normally distributed; a logarithmic transformation was applied (in base 2), with 
each unit increase in log2-albuminuria representing a doubling of ACR.  
Results: 591 participants were assessed (71% Aboriginal, 61.6% female, mean age 
45.1 years, BMI 30.2 kg/m2, WHR 0.94, eGFR 99.2 ml/min/1.73m2).  The overall 
prevalence of albuminuria, diabetes, microscopic-haem and ACEI/ARB use was 
41.5%, 41.5%, 17.8% and 34.7% respectively; 69.3% of adults with albuminuria and 
diabetes received an ACEI/ARB.  Using multivariable linear regression modelling, 
the potentially modifiable factors independently associated with log2-albuminuria 
were microscopic-haem, diabetes, WHR, systolic BP, alkaline phosphatase (all 
positive) and eGFR (inverse).   
Conclusion: Albuminuria is associated with diabetes, central obesity and 
haematuria.  High ACEI/ARB prescribing for adults with diabetes and albuminuria 
was observed.  Further understanding of the links between fat deposition, 
haematuria and albuminuria is required.   
 
Introduction 
Albuminuria is an indicator of microvascular injury1, the metabolic syndrome, diabetic 
and non-diabetic chronic kidney disease (CKD) and excess cardiovascular disease 
mortality2-4.  Guidelines have recently recommended CKD screening and staging 
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using both albuminuria and estimated glomerular filtration rate (eGFR)2.  Local and 
national clinical management guidelines for CKD also recommend renoprotective 
medication use5, 6.   
Albuminuria without impaired GFR7, or which precedes diabetes is a common CKD 
presentation in Aboriginal and Torres Strait Islander (TSI) people of northern 
Australia.  In this population, albuminuria has been linked with overweight, dialysis 
dependent end stage kidney disease (ESKD) and mortality8, 9.  Understanding the 
associations of albuminuria among Aboriginal and Torres Strait Islander people, 
such as the consistency of clinical prescribing practices for adults with CKD, may 
highlight health system and broader health promotion measures for ESKD 
prevention.  Our aim was to describe the clinical, anthropometric and biochemical 
associations of albuminuria among volunteering Aboriginal and Torres Strait Islander 
adults within different levels of kidney function living across large regions of northern 
and Central Australia.   
 
Methods 
Participants 
The life expectancy gap attributed to adult chronic diseases has contributed to a 
younger median age of Indigenous Australians than other Australians (21 v 37 
years)10.  As such, annual health assessments are recommended for Indigenous 
Australian adults (from the age of fifteen)11.  Reflecting the different age structures 
and risks associated with chronic disease, participants in the eGFR Study were self-
identifying Aboriginal and Torres Strait Islander people (Indigenous Australians) 
aged at least 16 years12.  With the exception of adults undertaking dialysis, who had 
rapidly changing kidney function or were pregnant or breastfeeding, all adults 
expressing interest to participate were able to be stratified for inclusion, including 
those with diabetes or existing kidney disease.  Recruitment areas focussed on 
regions with a high incidence of ESKD13, including more than 20 sites in the Northern 
Territory, Central Australia, Thursday Island and Far North Queensland, and the 
Kimberley and Goldfield regions of Western Australia.  Although Aboriginal and 
Torres Strait Islander peoples are both recognised as Indigenous peoples of 
Australia, there are several unique features including population origins (Micronesia 
v Melanesia origins), cultural practises14 and patterns of dyslipidaemia15.  Torres 
Strait Islander peoples are also a minority group within the Indigenous Australian 
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population16, however it was not the goal of the eGFR Study to recruit equal 
numbers of TSI and Aboriginal participants.  Participants provided informed consent.  
Ethics approval was provided by the Northern Territory Department of Health and 
Families and Menzies School of Health Research Human Research Ethics 
Committee, including the Indigenous ethics subcommittee, which has the power of 
veto over studies involving Indigenous Australian peoples; Cairns and Hinterland 
Health Services District Human Research Ethics Committee; Central Australian 
Human Research Ethics Committee; Western Australian Aboriginal Health 
Information and Ethics Committee; Royal Perth Hospital Ethics Committee. 
 
Measures 
Diabetes was defined by HbA1c≥48 mmol/mol17 or physician diagnosis or by current 
use of anti-diabetic medications.  Hypertension was defined by physician diagnosis, 
current use of anti-hypertensive medications or BP≥140/90 mmHg18.  Blood pressure 
was described as the mean of three resting blood pressure measurements (taken at 
least 3 minutes apart) after the participant had been seated quietly for at least 5 
minutes using an automated sphygmomanometer as previously described12.  Current 
smoking was self-reported.  Smoking duration in years was calculated in current 
smokers.  Alcohol excess was recorded if participants recorded no alcohol free-
days19 or >20 units consumed per week.  Remoteness index of usual residence was 
calculated by Accessibility Remoteness Index of Australia with scores >10.53 
indicating residence in a community/ town in very remote Australia20.  Urine dipstick 
was used as a screening test to evaluate for the presence of chronic kidney 
disease21.  Urine samples were sent for urine culture if urine dipstick was positive for 
either of nitrites, leucocytes or haem.  We describe microscopic-haem as the 
presence of at least trace haem on urine dipstick, in the absence of bacteriuria 
defined by the presence of a single bacterial colony count of ≥105/ml.  In this 
analysis, bacteriuria is not urinary tract infection.  Medication prescriptions for 
aspirin, HMG-CoA enzyme reductase inhibitors (statins), non-steroidal anti-
inflammatory drugs (NSAID’s), antihypertensive medications including angiotensin 
converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists (ARB) 
were confirmed by the medical record.  ACEI/ARB described the prescription with 
either an ACEI or ARB.  Measurements of resting blood pressure, height, weight, 
waist and hip circumferences and bioimpedance were collected; waist to hip ratio 
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(WHR), body mass index (BMI) and fat-free mass percent (FFM%)22 were 
calculated.  An optimal FFM% range for healthy middle-aged adults (40-59 years) 
with BMI 18-25 kg/m2 in males (79-89%) and females (65-76%) has been previously 
described23.   
 
Laboratories local to each recruitment site measured non-fasting serum high density 
lipoprotein (HDL)-cholesterol, glycated haemoglobin (HbA1c), liver function tests and 
urine albumin to creatinine ratio (ACR).  Detailed methods at each laboratory for 
these measures have been previously described12, and each pathology laboratory 
was accredited by NATA (National Association of Testing Authorities, Australia).  
Albuminuria was defined as an ACR>3.0 mg/mmol2.  Serum creatinine was 
measured centrally using an IDMS standardised enzymatic assay24, and estimated 
GFR (eGFR) was calculated by the CKD-EPI formulae without use of the correction 
for African Americans24. 
 
Six hundred and fifty three Indigenous Australian participants were assessed at the 
baseline eGFR Study.  This analysis describes adult participants defined as at least 
18 years, since creatinine-derived variables (eGFR) are not validated in populations 
younger than 18 years.  Thus this analysis describes 591 participants accounting for 
the following exclusions: age<18 years (n=10); missing data for urine ACR (n=46); 
presence of bacteriuria confirmed by urine culture (n=6).  
 
Statistical Analyses 
Descriptive characteristics of participants were reported by Indigenous status 
(Aboriginal or TSI) and, within each indigenous group, separately for those without 
and with albuminuria.  Categorical variables were described with a percentage and 
continuous variables, when normally distributed, with mean and standard deviation. 
Continuous variables with a right skewed distribution were log transformed when 
possible, otherwise were described with median and interquartile range. P values 
were derived to test differences in distribution of participants’ characteristics between 
those with and without albuminuria using Chi-squared test for categorical factors and 
Students t-test for normally distributed continuous factors. The Wilcoxon rank-sum 
test was used to compare medians in not normally distributed variables.   
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The outcome of ACR displayed a highly right skewed distribution, thus a logarithmic 
transformation in base 2 (log2-albuminuria) was carried out to normalise the 
distribution.  Therefore each unit rise in log2-albuminuria represents a doubling in 
ACR.   
 
As the cohort had a higher proportion of females, and aging is associated with 
chronic disease and adiposity, we used linear regression models, adjusted for age 
and gender in each indigenous group to examine the effect each variable had on 
log2-albuminuria, and identify which variables had different coefficient loadings 
between indigenous groups.  A multivariable linear regression analysis was then 
used to examine the associations between participants’ characteristics and the 
outcome, log2-albuminuria.  The initial model was built with gender, ethnicity and 
age, and all other predictor variables identified on linear modelling with p<0.10.  
Using a stepwise backwards process, the final significant model was obtained by 
removing one variable at a time if its main effect in the model was p>0.05, until all 
remaining variables were significantly associated with the outcome (p<0.05).  We 
assessed and did not observe an interaction between indigenous ethnicity and the 
other covariates. Collinearity between predictor variables was assessed using the 
variance of inflation factor, a maximum value of 10 being deemed acceptable.  To 
enhance the clinical interpretation, we subsequently converted the equation from 
log2-albuminuria to ACR as the outcome variable, in order to demonstrate the 
contribution (as percent additive contribution) of each independent variable with 
estimated ACR (in mg/mmol).  Statistical analyses were performed using Stata v14 
(Stata Corporation, College Station, TX). 
 
Results 
Albuminuria, diabetes, hypertension and overweight were key findings observed 
among the 591 participants (Table 1).  The median (IQR) ACR in Aboriginal and TSI 
participants was 2.5 (0.7, 30.4) and 1.1 (0.6, 4.6) mg/mmol respectively (p<0.001).  A 
higher proportion of older participants (>60 years) and Aboriginal participants had 
albuminuria and low eGFR (<60 ml/min/1.73m2) (Table 2).  Microscopic-haem was 
observed in 17.8% of participants overall, including in adults with and without 
albuminuria (23.9%, 13.5%, p=0.002).  A wide range in FFM% was observed in 
participants (49-94%), though FFM% overall was lower in Aboriginal than TSI 
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participants (Aboriginal, mean (SD): 64.9 (9.7) % v TSI: mean (SD): 66.9 (9.4) %, 
p=0.03).  As expected, FFM% was higher in males than females (74 (8.3) v 60.3 
(6.0) %, p<0.001).  ACEI/ARB’s were the most commonly prescribed class of 
antihypertensive medications (Table 3).  The highest frequency of medication 
prescription for ACEI/ARB, statins and aspirin was observed in adults with 
albuminuria who also had diabetes (Figure 1).   
 
Characteristics of participants with albuminuria (ACR>3.0 mg/mmol) included older 
age, diabetes, hypertension, abdominal obesity, use of ACEI/ARB and statins, higher 
values each of systolic and diastolic blood pressure, HbA1c and alkaline 
phosphatase, and lower eGFR (Table 3).  Albuminuria was also associated with 
higher WHR (without a comparably higher value in BMI or weight) in Aboriginal male 
and female participants.  In contrast, TSI males with albuminuria had a larger body 
size marked by higher adiposity (indicated by higher weight, higher BMI and lower 
FFM%) in addition to higher WHR than TSI males with normoalbuminuria.  By 
comparison (and unlike Aboriginal females), albuminuria in TSI females was not 
significantly associated with WHR (Table 3). 
 
Bivariate analysis showed significant associations between log2-albuminuria and 
WHR (r=0.34) and serum GGT (r=0.19) respectively.  GGT was also positively 
associated with WHR (r=0.26), ALP (r=0.40) and diabetes (35 v 29 U/L, p=0.017).  
Bilirubin was inversely associated with ALP (r= -0.19).  High serum GGT (>50 U/L) 
was observed in 31% of participants, though reporting of excess alcohol 
consumption was low in participants (n=49, 8.3%). 
 
Linear Regression modelling adjusted for age and gender 
Log2-albuminuria when adjusted for age and gender, was independently associated 
with the following variables in all participants (p≤0.001): microscopic-haem, diabetes, 
WHR, total cholesterol, aspirin use, statin use, ACEI/ARB use, hypertension, systolic 
BP, diastolic BP, HbA1c, HDL-cholesterol, alkaline phosphatase, GGT, triglycerides, 
(all positive) and eGFR (inverse) and bilirubin (inverse); and at the level of p<0.10 as 
follows: waist (p=0.06) and total protein (p=0.07).  Differences in the coefficient 
loading between Indigenous groups (beta coefficient, Aboriginal, TSI) were noted 
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respectively for: diabetes (2.54, 1.46), microscopic-haem (2.0, 1.0), WHR (8.12, 
7.40), aspirin use (1.87, 0.92) and total cholesterol (-0.37, -0.13).   
 
Log2-albuminuria when adjusted for age and gender, was not linearly associated in 
the aggregate group with: height (p=0.10), alanine transferase (p=0.14), remoteness 
index (p=0.16), HDL: total cholesterol ratio (p=0.21), FFM% (p=0.32), current 
smoking (p=0.56), NSAID use (p=0.72), weight (p=0.74) and body mass index 
(p=0.94).   
 
In the multivariable linear regression model in all participants (Table 4), 56% of the 
variance in log2-albuminuria was explained by Aboriginal ethnicity, female sex, 
WHR, systolic blood pressure, diabetes, ACEI/ARB use, ALP and microscopic-haem 
(all were positive associations), and lower eGFR.  ACEI/ARB use explained 2.2% of 
the 56% variance in log2-albuminuria among all participants.  Table 5 shows the 
contribution of each independent variable with estimated ACR (as an untransformed 
variable in mg/mmol).  For example, using the simulated patients, with all measures 
being equal, diabetes explained an additive 186% higher estimated ACR than the 
value observed in participants without diabetes (patient 6 v 5: ACR 13 mg/mmol v 5 
mg/mmol).  
 
Discussion 
We examined the cross-sectional associations of albuminuria among 591 Indigenous 
Australian adults of the eGFR Study, who were recruited across multiple northern 
and Central Australian sites and had fulfilled the pre-defined recruitment criteria of 
good health, increased cardio-metabolic risk or CKD.  Of the ten factors identified in 
the multivariable linear regression model, the categorical factors strongly associated 
with estimated ACR as potential targets of disease prevention and mitigation were 
diabetes and microscopic-haem.  Furthermore systolic blood pressure, lower eGFR 
and higher WHR were the continuous variables which were most strongly associated 
with estimated ACR.  Other key findings of this analysis included the strong 
association of albuminuria with features of the metabolic syndrome among 
participants; the co-existence of microscopic-haem in a population with a high 
frequency of diabetes; and the high prescription rates of renoprotective agents 
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among adults with co-existing cardio-metabolic risks including diabetes, 
hypertension and albuminuria.   
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Albuminuria, ALP, GGT and central and total adiposity 
Alkaline phosphatase, GGT, uric acid and albuminuria are all biochemical markers 
associated with the metabolic syndrome25-27.  GGT and ALP are both correlated with 
abdominal adiposity27 and GGT can indirectly predict ultrasound-proven hepatic 
steatosis28, a condition within the metabolic syndrome spectrum.  In one remote 
Aboriginal community, it was previously reported that albuminuria was positively 
associated with several cardio-metabolic disease risk markers: blood pressure, uric 
acid, diabetes, CRP and serum GGT (p=0.05)29.  Additionally, comparable 
decreases in GGT concentrations over time were associated with lower waist 
circumference among Indigenous adults of north Queensland30.  We suggest hepatic 
steatosis is likely among Aboriginal participants when overweight, given the positive 
association of GGT and ALP with WHR and log2-albuminuria in our study.  This may 
result from a low threshold for hepatic lipid storage resulting in preferential central 
adiposity that accompanies elevated fasting insulin concentrations.  It is proposed 
that these elevated insulin concentrations are to historically mitigate periods of 
recurrent relative low food intake31.  A low threshold for hepatic lipid storage may 
also be consequent to limited peripheral adipose storage depots, due to a lower 
absolute lean mass.   
 
Log2-albuminuria was strongly associated with WHR in the multivariate regression 
model, which is an observation consistent among Aboriginal people across northern 
and Western Australia32.  Among Aboriginal participants, this central fat distribution 
(at comparably lower BMI than TSI participants) is likely to be a progression of the 
physique described by Piers et al. who reported a higher WHR, and percent fat 
adjusted for BMI in healthy Aboriginal young adults relative to Caucasian 
participants33. 
 
In this analysis, overweight was a common feature of participants, indicated by high 
WHR, BMI and low FFM%.  These low FFM% values were comparable to previous 
reported values in Aboriginal adults of similar age and BMI34, 35.  Consistent with 
other studies, we report a higher FFM% in TSI than Aboriginal participants36.  We 
note adults with higher (than lower) FFM% have an enhanced capacity for insulin 
secretion37.  This might suggest TSI groups have an optimised capacity for insulin 
clearance across a larger weight-range due to a higher proportion of lean mass than 
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Aboriginal people36, and is consistent with the lack of association of log2-albuminuria 
with FFM% in participants in this analysis.    
 
Central obesity (than total obesity) was previously reported to be more strongly 
associated with cardio-metabolic risk across multi-ethnic populations38.  Likewise, we 
show that albuminuria is associated with WHR and ALP (and not with FFM%).  WHR 
in combination with ALP may have better defined the physical attributes related to 
the metabolic syndrome of each indigenous group.  The Aboriginal ethnicity 
covariate may have further explained the difference in body fat distribution between 
groups. 
 
Microscopic haem  
Albuminuria was observed in participants with and without diabetes and with and 
without microscopic-haem as detected by urine dipstick.  This association is 
consistent with the leading clinical diagnoses of Indigenous Australians with ESKD39, 
and also consistent with the mixed and overlapping renal pathologies in biopsy 
series of remote living Aboriginal people with diabetes40.  One remote Aboriginal 
community with a high risk of ESKD had documented haematuria amongst 25% of 
adults41.  A greater understanding of the pathogenic impact of microscopic-haem in 
diabetic and non-diabetic CKD in both Indigenous groups is needed.   
 
Renin-Angiotensin system blockade 
As in other populations, angiotensin converting enzyme inhibitors have 
demonstrated renoprotective effects in Aboriginal Australians42, 43, and are the 
cornerstone of medical treatment guidelines for adults with CKD5.  The use of an 
ACEI/ARB is in large part a treatment decision for cardio-metabolic risk modification 
related to albuminuria, diabetes, and hypertension.  The extent to its use may vary 
according to the health service provider awareness and vigour.  In this analysis, 
there was high alignment with guidelines for ACEI/ARB prescribing for adults with 
diabetes, which were often co-prescribed with statins and aspirin.  The majority of 
albuminuric participants without diabetes had micro-albuminuria (ACR 3-30 
mg/mmol) and preserved eGFR.  In this group ACEI/ARB prescribing practices were 
again consistent with local and national guidelines, since their use is not 
recommended for normotensive, non-diabetic adults with micro-albuminuria and 
 This article is protected by copyright. All rights reserved. 
preserved eGFR5, 6.  This cross-sectional analysis reports the positive association of 
ACEI/ARB use with albuminuria.  We suggest ACEI/ARB are beneficial agents, and 
the model identifies they are being used substantially for the treatment of 
albuminuria or conditions associated with albuminuria (including diabetes and 
hypertension).  The lower frequency of current smokers in adults with albuminuria 
suggests participants’ engagement in health education strategies.   
 
Several key strengths of this study suggest generalisability of our findings.  We 
assessed a large cohort, involving sites across five major Australian regions, and 
included participants with a wide range of eGFR, and used measures validated in 
Indigenous Australians (FFM%, eGFR).  We have highlighted the key modifiable 
factors associated with albuminuria in Indigenous Australians, and the between-
group differences of albuminuria in this population, which is relevant in informing 
health intervention strategies.  Some limitations are acknowledged; the study was 
not intended to be population representative, and our findings may be subject to 
volunteer bias thereby limiting generalisability.  We recruited 653 Indigenous 
participants in the eGFR study, and the 62 participants who were excluded from this 
analysis (due to missing ACR values, young age or bacteriuria) were younger and 
had a lower WHR.  Furthermore, the final multivariable regression model describes 
517/591 participants with complete data for all 10 variables.  The serum alkaline 
phosphatase concentration was higher in participants included in the final model, 
which may affect the strength of association of the factors with log2-albuminuria.  In 
this analysis the description of microscopic-haem was based on urine dipstick rather 
than the gold standard measure defined as microscopic urinary red blood cells ≥3-
5/HPC on centrifuged urine.  Albuminuria and microscopic-haem were measured 
once, thus misclassification was possible, but minimised by independent medical 
record review.  It was not possible to distinguish microscopic-haem as glomerular or 
lower urinary tract origin, or explore the association of albuminuria with diet, weight 
trajectory or other lifestyle factors.  
 
Conclusions 
We report a strong cross-sectional association of log2-albuminuria with abdominal 
obesity, diabetes and microscopic-haem among Indigenous Australian participants 
who are relatively younger than other populations with chronic kidney disease.  
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There was also high ACEI/ARB use in adults with diabetes and albuminuria.  
Although the mechanisms linking albuminuria, abdominal obesity and fatty liver 
remain to be elucidated, these associations were striking in participants.  Further 
understanding of the links between fat deposition, haematuria and albuminuria is 
required, in order to strengthen the public health strategies for obesity, diabetes and 
CKD.   
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Figure 1: Medication prescription among participants by albuminuria and diabetes 
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Table 1: Participant characteristics 
 
 n (%) 
Aboriginal Ethnicity  419 (70.9%) 
Female sex  364 (61.6%) 
Usual residence: very remote  344 (59.6%) 
Diabetes 245 (41.5%) 
Hypertension 255 (43.1%) 
Albuminuria ⱡ 245 (41.5%) 
New Case 122 (49.8%) 
Prevalent Case 100 (40.8%) 
Haematuriaⱡⱡ   99 (17.8%) 
eGFR<60 ml/min/1.73m2 ⱡⱡ 103 (17.5%) 
BMI >25 km/m2 450 (76.6%) 
 Mean (standard deviation) 
Age, years 45.1 (14.6) 
eGFR⌠, ml/min/1.73m2 ⱡⱡ 99.2 (79.8-112.3) 
ACR⌠, mg/mmol 1.9 (0.7-17.3) 
HbA1c, mmol/mol 50 (19.6) 
Systolic BP, mmHg 118 (18) 
Diastolic BP, mmHg 75 (10) 
BMI, kg/m2 30.2 (7.2) 
FFM % males 64.4 (11.4) 
FFM % females 48.1 (9.0) 
WHR males  0.98 (0.09) 
WHR females 0.92 (0.08) 
Data are number (%) or mean (SD) or ⌠median (interquartile range). n=591.  
ⱡⱡIncomplete data as follows: usual residence category (577), haematuria 
(556), eGFR (589), HbA1c (575), blood pressure (582), BMI (587), FFM% 
(524), WHR (560).   ⱡUnable to categorise albuminuria as incident or 
prevalent in n=23/245 (9.4%) participants.  Abdominal obesity is defined by 
WHR>0.90 in males and >0.85 in females and/or BMI>30kg/m2 26 
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Table 2: The distribution of participants by female gender, albuminuria and low eGFR, and by indigenous ethnicity, age and BMI 
 
  Indigenous group Age (years) Body Mass Index (kg/m2) 
 
n 
TSI 
n=172 
Aboriginal 
n=418 p 
<60  
n=492 
≥60  
n=99 p 
<25  
n=137 
≥25  
n=450 p 
Female N=364 58.7% 62.8% 0.36 61.3%  62.6% 0.81 51.1% 64.9% 0.004 
Albuminuria N=245 27.9% 47% <0.001 36.6% 65.7% <0.001 42.3% 40.9% 0.76 
eGFR<60 ml/min/1.73m2 N=103 12.3% 19.6% 0.03 11.6% 46.5% <0.001 22.6% 15.6% 0.058 
Total participants are n=591; data are incomplete: BMI (n=587), eGFR (n=589)  
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Table 3: Descriptive characteristics participants without and with albuminuria, by ethnicity and gender  
   Aboriginal Torres Strait Islander 
 
 Female  Males 
 
Females  Males  
 
 Normo-
albuminuria 
Albuminuria P 
value 
Normo-
albuminuria 
Albuminuria P  
value 
Normo-
albuminuria 
Albuminuria P 
value 
Normo-
albuminuria 
Albuminuria P 
value 
 n N=141 N=122 N=81 N=75 N=70 N=31 N=54 N=17 
 n(%)       
Very remote residence 577 69 (50.4) 58 (48.7) 0.795 45 (55.6) 35 (48) 0.345 60 (87.0) 23 (74.2) 0.116 41 (80.4) 13 (81.3) 0.940 
Diabetes  591 34 (24.1) 84 (68.9) <0.001 15 (18.5) 49 (65.3) <0.001 20 (28.6) 19 (61.3) 0.002 13 (24.1) 11 (64.7) 0.002 
Hypertension 585 40 (28.4) 85 (69.7) <0.001 18 (22.2) 50 (66.6) <0.001 19 (27.1) 16 (51.6) 0.017 17 (31.5) 10 (58.8) 0.043 
Current smoking 580 64 (46.4) 39 (32.8) 0.026 42 (51.9) 32 (43.2) 0.284 27 (38.6) 7 (23.3) 0.140 25 (48.1) 3 (18.8) 0.037 
Microscopic-haem  556 24 (17.9) 30 (26.3) 0.110 2 (2.8) 15 (20.8) 0.001 12 (18.2) 7 (25.9) 0.400 6 (11.8) 3 (17.7) 0.535 
Medication Prescription              
Any BP medication 591 28 (19.5) 75 (61.4) <0.001 14 (17.3) 49 (65.3) <0.001 12 (17.1) 19 (61.3) <0.001 11 (20.4) 9 (52.9) 0.009 
ACEI/ARB 591 26 (18.4) 73 (59.8) <0.001 14 (17.3) 45 (60.0) <0.001 10 (14.3) 18 (58.1) <0.001 10 (18.5) 9 (52.9) 0.005 
Statin 591 23 (16.3) 49 (40.2) <0.001 7 (8.6) 33 (44.0) <0.001 11 (15.7) 14 (45.2) 0.002 9 (16.7) 8 (47.1) 0.010 
Aspirin  591 18 (12.8) 36 (29.5) 0.001 9 (11.1) 34 (45.3) <0.001 14 (20) 12 (38.7) 0.047 9 (16.7) 6 (35.3) 0.101 
NSAID 591 2 (1.4) 2 (1.6) 0.884 2 (2.5) 1 (1.3) 0.606 1 (1.4) 0 (0) 0.504 2 (3.7) 2 (11.8) 0.209 
 Mean (Standard deviation)       
Age (years) 591 42.0 (13.5) 51.0 (13.6) <0.001 37.9 (13.3) 50.8 (13.9) <0.001 42.7 (13.7) 49.3 (14.7) 0.033 40.7 (15.8) 52.4 (10.5) 0.006 
Height (cm) 587 163.1 (7.2) 161.7 (6.1) 0.086 172.5 (5.3) 172.0 (6.7) 0.001 161.9 (5.8) 161.6 (5.0) 0.82 173.6 (6.4) 173.9 (6.0) 0.88 
Weight (kg) 589 79.9 (19.2) 78.9 (19.5) 0.68 83.2 (20.2) 86.3 (21.8) 0.35 84.5 (19.5) 91.3 (21.2) 0.12 93.0 (24.8) 108.6 (18.7) 0.02 
BMI 587 29.9 (6.5) 30.2 (7.3) 0.78 26.9 (6.1) 29.0 (6.8) 0.046 32.2 (6.8) 35.0 (8.0) 0.073 30.8 (8.0) 35.8 (5.3) 0.02 
Waist (cm) 564 99.6 (14.7) 102.6 (15.9) 0.13 96.0 (17.8) 104.0 (15.5) 0.003 100.0 (15.6) 104.3 (13.8) 0.20 100.8 (18.5) 117.0 (12.2) 0.002 
Waist-hip ratio 560 0.91 (0.08) 0.95 (0.09) 0.001 0.95 (0.10) 1.03 (0.08) <0.001 0.88 (0.07) 0.91 (0.09) 0.241 0.94 (0.08) 1.03 (0.05) <0.001 
Fat free mass (%)  524 60.1 (5.9) 59.5 (5.8) 0.38 75.1 (7.9) 72.8 (8.7) 0.12 61.8 (6.5) 61.5 (6.2) 0.85 75.2 (8.9) 70.2 (3.7) 0.034 
SBP (mmHg) 582 113 (15) 124 (20) <0.001 117 (14) 127 (21) 0.001 109 (15) 122 (4) 0.001 117 (15) 129 (16) 0.013 
DBP (mmHg) 582 74 (10) 77 (10) 0.026 74 (10) 78 (12) 0.044 69 (8) 75 (9) 0.002 73 (10) 79 (12) 0.03 
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HbA1c (mmol/mol) 575 45.1 (15.4) 56.8 (21.2) <0.001 42.1 (8.6) 59.3 (23.2) <0.001 45.6 (18.7) 59.9 (24.8) 0.003 42.5 (11.7) 66.5 (28.4) <0.001 
Total Cholesterol (mmol/L) 571 4.9 (1.2) 4.5 (1.0) 0.002 5.0 (1.0) 4.5 (1.0) 0.003 5.0 (0.9) 5.2 (1.2) 0.357 5.1 (0.9) 4.7 (1.0) 0.162 
HDL-Cholesterol (mmol/L) 556 1.14 (0.37) 1.08 (0.31) 0.14 1.10 (0.31) 1.00 (0.30) 0.047 1.16 (0.35) 1.02 (0.23) 0.076 1.07 (0.34) 0.86 (0.17) 0.025 
Total Cholesterol/HDL ratio 557 4.7 (1.6) 4.5 (1.3) 0.24 4.8 (1.4) 4.8 (1.7) 0.99 4.6 (1.4) 5.3 (1.3) 0.037 5.2 (1.6) 5.6 (1.2) 0.29 
Total Protein (g/L) 585 78 (11) 81 (11) 0.068 76 (17) 78 (12) 0.43 73 (4) 73 (6) 0.99 73 (16) 72 (19) 0.82 
Alkaline phosphate (U/L) 579 105(32) 131(42) <0.001 98 (29) 114(35) 0.003 77 (20) 91 (18) 0.001 81(23) 89(24) 0.27 
Alanine Transferase (U/L) 583 26 (14) 28 (18) 0.30 35 (20) 34 (26) 0.90 27 (14) 29 (18) 0.56 36 (19) 30 (14) 0.26 
  Median (interquartile range)       
Cigarettes (per day*) 580 10 (6.5, 20) 12 (5.5, 20) 0.84 15 (6, 25) 13.5 (5.5, 25) 0.62 10 (4, 17) 8 (6, 25) 0.37 8 (5, 15) 4 (3, 25) 0.60 
Smoking duration (years)* 559 19 (10, 28) 22 (15, 33) 0.05 17.5 (11, 25) 26 (18, 35) 0.006 16 (10, 21) 12 (8, 29.6) 0.56 14 (6, 28) 34 (25, 48.5) 0.09 
Creatinine (µmol/L) 584 58 (53, 68) 70 (56, 125) <0.001 81 (71, 90) 95.5 (74, 159) <0.001 60 (54, 64) 64.5 (57, 98) 0.021 88 (79, 93) 108 (78, 140) 0.052 
eGFR (ml/min/1.73 m
2
) 584 105 (93, 116) 90 (39, 108) <0.001 106 (93, 115) 84 (38, 105) <0.001 105 (96, 116) 95 (57, 112) 0.01 98 (84, 110) 69.5 (49, 101) 0.003 
γ glutamyl transferase (U/L) 585 32 (25, 52) 41 (28, 75) 0.007 47 (28, 77) 57 (30, 89) 0.09 21 (16, 28) 25 (19, 34) 0.10 29 (22, 40) 25 (19, 35) 0.22 
 Geometric Mean (95% Confidence interval)       
Triglycerides (mmol/L) 
571 
1.77 
(1.63, 1.92) 
2.06 
(1.88, 2.25) 
0.015 
1.79 
(1.59, 2.02) 
2.41 
(2.11, 2.76) 
0.003 
1.36  
(1.18, 1.56) 
1.73  
(1.45, 2.07) 0.054 
1.56  
(1.32, 1.85) 
2.16  
(1.73, 2.70) 0.057 
Bilirubin (µmol/L) 579 5.4 (5.0, 5.8) 4.8 (4.4, 5.2) 0.038 7.2 (6.6, 7.9) 5.9 (5.2, 6.7) 0.14 8.9 (8.2, 9.7) 7.7 (6.7, 8.9) 0.084 10.7 (9.7, 11.9) 9.8 (8.5, 11.4) 0.41 
 * For  current smokers 
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Table 4: Multivariable linear regression model of log2-albuminuria in all participants 
 
  
 
Β Coefficient 95% Confidence Interval p 
Aboriginal ethnicity 0.53 0.09 0.97 0.017 
Age (years) -0.02 -0.04 -0.01 0.012 
Female 0.20 -0.23 0.62 0.359 
Microscopic-haem 1.30 0.81 1.79 <0.001 
Diabetes  1.52 1.06 1.98 <0.001 
Use of ACEI /ARB 1.24 0.77 1.71 <0.001 
Systolic BP (mmHg) 0.03 0.02 0.04 <0.001 
eGFR (ml/min/1.73m2) -0.04 -0.05 -0.03 <0.001 
WHR  2.75 0.25 5.26 0.032 
Alkaline phosphatase (U/L) 0.01 0.003 0.015 0.001 
Constant -2.99 -5.80 -0.18 0.037 
 Model R2 0.56;  n=517 
Variables in the initial model were selected if they were linearly associated with log2-albuminuria (adjusted for age and gender) in all participants with a p value <0.10 as 
follows:  microscopic-haem, diabetes, hypertension, ACEI/ARB use, statin use, aspirin use, systolic blood pressure (BP), diastolic BP, eGFR, HbA1c, triglycerides, total 
cholesterol, HDL-cholesterol, waist, WHR, serum total bilirubin, alkaline phosphatase (ALP), gamma glutamyl transferase, total protein.  Age, gender and indigenous 
ethnicity (Aboriginal =1, TSI=0) were forced in the model.  Categorical variables were coded 1=present, 0=absent; continuous variables were included in equation in 1 unit 
increments. 
Log2-albuminuria was converted to ACR (in mg/mmol) using ACR=exp(equation x log2
).  Thus ACR (mg/mmol) is represented as follows: 
ACR= exp
[(0.53(if Aboriginal) -0.02 (age) + 0.20 (if female) + 1.30 (if microscopic- haem) + 1.52 (if diabetes) + 1.24 (if ACEI/ARB use) + 0.03 (systolic BP) – 0.04 (eGFR) + 2.75 (WHR) + 0.01 
(ALP) -2.99) X log
2
] 
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Table 5: Clinical interpretation of effect of each factor on ACR (mg/mmol) and examples of possible real clinical cases 
 
Additive contribution of each independent 
variable to estimated ACR expressed as a 
percentage increase 
 Simulations (individual patients) 
 Additional percentage to estimated 
ACR relative to preceding simulated 
client 95% CI   
 
1 2 3 4 5 6 7 8 9 10 11 
 
Aboriginal ethnicity 47 9 98 
 
TSI 
Aborigin
al 
Aborigin
al 
Aborigin
al 
Aborigin
al 
Aborigin
al 
Aborigin
al 
Aborigin
al 
Aborigin
al 
Aborigin
al 
Aborigin
al 
 Female sex 15 -14 54 
 
Male Male Female Female Female Female Female Female Female Female Female 
 Age (-10 years) 16 4 27 
 
45 45 45 55 55 55 55 55 55 55 55 
 
Microscopic-haem 146 76 243 
 
Absen
t 
Absent Absent  Absent  
Presen
t 
Presen
t 
Presen
t 
Presen
t 
Presen
t 
Presen
t 
Presen
t 
 
Diabetes 186 108 293 
 
Absen
t 
Absent Absent Absent  Absent  
Presen
t 
Presen
t 
Presen
t 
Presen
t 
Presen
t 
Presen
t 
 
ACEI/ARB 136 70 227 
 
Absen
t 
Absent Absent Absent Absent Absent 
Presen
t 
Presen
t 
Presen
t 
Presen
t 
Presen
t 
 Systolic BP (+10 
mmHg) 24 16 31 
 
125 125 125 125 125 125 125 135 135 135 135 
 eGFR (-10 
ml/min/1.73m2) 26 20 31 
 
90 90 90 90 90 90 90 90 80 80 80 
 WHR (+ 0.1 units) 21 1 43 
 
0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90 1.00 1.00 
 ALP (+ 10 U/L) 6 2 10 
 
115 115 115 115 115 115 115 115 115 115 125 
         
 
                      
 Estimated ACR (mg/mmol) 
 
1.3 1.9 2.18 1.87 4.58 13.12 30.96 39.09 50.64 61.03 64.87 
                
Interpretation: In this population, compared to client 1, client 2 has 147% higher estimated ACR (1.9 v 1.3 mg/mmol), thus Aboriginal ethnicity has a 47% 
additive contribution to ACR than the TSI client indicated by client 1.  Compared to client 2, client 3 has 115% higher estimated ACR (2.2 v 1.9 mg/mmol), 
thus females sex has a 15% additive contribution to ACR in clients without diabetes in this population.  
 
 
